27.59
-0.29(-1.04%)
Currency In USD
| Previous Close | 27.88 |
| Open | 28.5 |
| Day High | 28.5 |
| Day Low | 26.81 |
| 52-Week High | 36.44 |
| 52-Week Low | 13.53 |
| Volume | 1.16M |
| Average Volume | 1.83M |
| Market Cap | 2.8B |
| PE | -6.26 |
| EPS | -4.41 |
| Moving Average 50 Days | 28.48 |
| Moving Average 200 Days | 22.58 |
| Change | -0.29 |
If you invested $1000 in Beam Therapeutics Inc. (BEAM) since IPO date, it would be worth $1,471.47 as of February 21, 2026 at a share price of $27.59. Whereas If you bought $1000 worth of Beam Therapeutics Inc. (BEAM) shares 5 years ago, it would be worth $249.89 as of February 21, 2026 at a share price of $27.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
GlobeNewswire Inc.
Jan 11, 2026 10:00 PM GMT
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 9:01 PM GMT
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will p
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Dec 06, 2025 1:00 PM GMT
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Durable for up to 20 Months Patients Requ